Coxsackievirus A21 used as an oncolytic immunotherapy for cancer
Oncolytic viruses selectively target and kill cancer cells by direct lysis and by stimulating a tumour antigen specific immune response. These promising therapeutic agents target multiple cancers and one such agent, T-Vec (Talimogene laherparepvec) has been licensed for treatment of malignant melano...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
University of Surrey
2018
|
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.759498 |